Teva Pharmaceutical (NYSE: TEVA) reported Q4 EPS of $1.32, $0.01 worse than the analyst estimate of $1.33. Revenue for the quarter came in at $5.2 billion versus the consensus estimate of $5.26 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

Earnings

Canaccord Genuity Downgrades Teva Pharma (TEVA) to HoldFebruary 8, 2013 7:17 AM